Evidence map›Paper›PMID 38182877›Full record

ArticleScientific reports2024

Dapagliflozin ameliorates diabetes-induced spermatogenic dysfunction by modulating the adenosine metabolism along the gut microbiota-testis axis.

Zirun Jin, Yalei Cao, Qi Wen, Haitao Zhang, Zhuofan Fang, Qiancheng Zhao, Yu Xi, Zhichao Luo, Hui Jiang, Zhe Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Zirun Jin *Department of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Yalei Cao *Department of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Qi Wen *Department of Obstetrics and Gynecology, Center for Reproductive Medicine, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, No.49 North Garden Road, Haidian District, Beijing, 100191, China.
Haitao ZhangDepartment of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Zhuofan FangDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, No.49 North Garden Road, Haidian District, Beijing, 100191, China.
Qiancheng ZhaoDepartment of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Yu XiDepartment of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Zhichao LuoDepartment of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Hui JiangDepartment of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China. jianghui@bjmu.edu.cn.
Zhe ZhangDepartment of Urology, Center for Reproductive Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China. zhezhang@bjmu.edu.cn.
Jing HangDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, No.49 North Garden Road, Haidian District, Beijing, 100191, China. hangjbysy@163.com.
Peking University · CNPeking University Third Hospital · CNPeking University First Hospital · CN

Funding

Beijing Nova Program 20220484160China Postdoctoral Science Foundation 2022M710259Key Clinical Projects of Peking University Third Hospital BYSYZD2023033National Key Research and Development Program of China 2021YFC2700203National Key Research and Development Program of China 2022YFC2702904National Natural Science Foundation of China 82071658National Natural Science Foundation of China 82071698National Natural Science Foundation of China 82101676National Natural Science Foundation of China 82271630Natural Science Foundation of Beijing Municipality 7222208
6 · The paper itself

Abstract

Male infertility is one of the most common complications of diabetes mellitus (DM). Dapagliflozin is widely used to manage the type II DM. This study aimed to assess the dapagliflozin's effects on the spermatogenesis by administering either dapagliflozin (Dapa) or vehicle (db) to male db/db mice, and using littermate male db/m mice as the control (Con). We further performed the integrative analyses of the cecal shotgun metagenomics, cecal/plasmatic/testicular metabolomics, and testicular proteomics. We found that dapagliflozin treatment significantly alleviated the diabetes-induced spermatogenic dysfunction by improving sperm quality, including the sperm concentration and sperm motility. The overall microbial composition was reshaped in Dapa mice and 13 species (such as Lachnospiraceae bacterium 3-1) were regarded as potential beneficial bacteria. Metabolites exhibited modified profiles, in which adenosine, cAMP, and 2'-deoxyinosine being notably altered in the cecum, plasma, and testis, respectively. Testicular protein expression patterns were similar between the Dapa and Con mice. In vivo results indicated that when compared with db group, dapagliflozin treatment alleviated apoptosis and oxidative stress in testis tissues by down-regulating 2'-deoxyinosine. This was further validated by in vitro experiments using GC-2 cells. Our findings support the potential use of dapagliflozin to prevent the diabetes-induced impaired sperm quality and to treat diabetic male infertility.

Indexed as

Diabetes MellitusGastrointestinal MicrobiomeInfertility, MaleAdenosineAnimalsBenzhydryl CompoundsGlucosidesHumansMaleMiceSemenSpermatogenesisSperm MotilityTestisAdenosineBenzhydryl CompoundsdapagliflozinGlucosides

Identifiers

PMID38182877
PMCPMC10770392
OpenAlexW4390619159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.